|
NOTICE: Annals of Oncology Supplement Reporting on 3rd International
Ovarian Cancer Consensus Conference - September 2004
Annals of Oncology: 3rd International Ovarian Cancer Consensus of the GCIG
History, scope and methodology of the 3rd International
Consensus Workshop on Ovarian Cancer 2004
2004 consensus statements on the management of ovarian
cancer: final document of the 3rd International Gynecologic
Cancer Intergroup Ovarian Cancer Consensus Conference
(GCIG OCCC 2004)
Clinical trials in ovarian carcinoma: requirements for
standard approaches and regimens
Clinical Trials in Ovarian Carcinoma: study methodology
Integration of new or experimental treatment options and
new approaches to clinical trials
3rd International Ovarian Cancer Consensus Conference:
outstanding issues for future consideration
The Gynecologic Cancer Intergroup (GCIG): history and
current status
Bibliography
1998-2006
GCIG References
Bacon M, Zee B, James K, Stuart G, Soroka D, Walsh W, Bacon E. A comparison of the neurological toxicities of cisplatin-paclitaxel and cisplatin-cyclophosphamide. Proc Am Soc Clin Oncol 18:369a, 1999.
Ref Type: Abstract
Keywords: OV.10/GYN/EORTC/intergroup
Notes: Abstract #1426
Bezjak A, Tu D, Bacon M, Osoba D, Zee B, Stuart G, Roy J, Piccart M, Eisenhauer E. Quality of Life in Ovarian Cancer Patients: Comparison of Paclitaxel Plus Cisplatin, With Cyclophosphamide Plus Cisplatin in a Randomized Study.
J Clin Oncol 22(22): 2004
Butler L, Bacon M, Carey M, Zee B, Tu D, Bezjak A. Determining the
relationship between toxicity and quality of life in an ovarian cancer
chemotherapy clinical trial.
J Clin Oncol 22(12):2461-2468, 2004.
Butler L, Bezjak A, Carey M, Bacon M, Zee B, Stewart D, Brundage M. Determining the relationship between toxicity and quality of life using OV10, an international ovarian cancer chemotherapy trial. Quality of Life Research 9(3):287, 2000.
Ref Type: Abstract
Keywords: EORTC/GYN/intergroup/OV.10/quality of life/International
Notes: Abstract #1175
Cassidy J, Vergote I, Bertelsen K, Stuart G, Baron B, Piccart M. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Presented: Int Gyn Cancer Soc 2002.
Ref Type: Abstract
Keywords: EORTC-GCG/GYN/intergroup/NCIC CTG/NOCOVA/OV.10/Scottish Group Investigators
Intraperitoneal Chemotherapy in Ovarian Cancer Remains Experimental
Martin Gore, Andreas du Bois, and Ignace Vergote
JCO Oct 1 2006:
45284530.
Randomized Trial of Two Intravenous Schedules of the Topoisomerase I
Inhibitor Liposomal Lurtotecan in Women With Relapsed Epithelial Ovarian
Cancer: A Trial of the National Cancer Institute of Canada Clinical Trials
Group
Graham G. Dark, A. Hilary Calvert, Robert Grimshaw, Christopher Poole, Ken
Swenerton, Stan Kaye, Robert Coleman, Gordon Jayson, Tien Le, Susan Ellard,
Marc Trudeau, Paul Vasey, Marta Hamilton, Terri Cameron, Emma Barrett,
Wendy Walsh, Lynn McIntosh, and Elizabeth A. Eisenhauer
J Clin Oncol 2005;23 1859-1866
du Bois A., J. Sehouli, B. Lund, F. Joly, J. Huober, T.S. Jensen, E. Levy, V. Heilmann, K. Boman, A.C. Hardy-Bessard, A. Burges, J. Mäenpää, E. Pujade-Lauraine, J. Pfisterer, M. Gropp, A. Staehle, P. Wimberger, C. Jackisch, B. Schmalfeldt, A. Belau, S. Loibl, K. Wollschlaeger, U. Canzler, J. Rochon for the GCIG Intergroup of AGO-OVAR, NSGO and GINECO. Paclitaxel-carboplatin-gemcitabine (TCG) as first-line treatment of ovarian cancer: a prospective multicenter phase II study (AGO-OVAR 8) followed by a prospectively randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO TCG, NSGO-OC-0102) comparing TCG with standard TC. Int J Gynecol Cancer 2005, 15 (Suppl. 3), 224-225
Addition of Epirubicin as a Third Drug to Carboplatin-Paclitaxel in
First-Line Treatment of Advanced Ovarian Cancer: A Prospectively Randomized
Gynecologic Cancer Intergroup Trial by the Arbeitsgemeinschaft
Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe
d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens
Andreas du Bois, Beatrice Weber, Justine Rochon, Werner Meier, Alain
Goupil, Sigrid Olbricht, Jean-Claude Barats, Walther Kuhn, Hubert Orfeuvre,
Uwe Wagner, Barbara Richter, Hans-Joachim Lueck, Jacobus Pfisterer, Serban
Costa, Willibald Schroeder, Rainer Kimmig, Eric Pujade-Lauraine
JCO Mar 1 2006: 1127-1135.
Eisenhauer E, Ten Bokkel-Huinink W, Swenerton K, Gianni L, Myles J, van der Burg M, Kerr I, Vermorken J, Buser K, Colombo N, Bacon M, Santabarbara P, Onetto N, Winograd B, Canetta R. European-Canadian randomized trial of Taxol in relapsed ovarian cancer: High vs. low dose and long vs. short infusion. Classic Papers & Current Comments 3(1):171-84, 1998.
Keywords: OV.9/GYN/International
Randomized phase II trial of carboplatin versus paclitaxel and carboplatin
in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo
Español de Investigación en Cáncer de Ovario) study
Gonzalez-Martin AJ, Calvo E, Bover I, Rubio MJ, Arcusa A, Casado A, Ojeda
B, Balana C, Martinez E, Herrero A, Pardo B, Adrover E, Rifa J, Godes MJ,
Moyano A, Cervantes A.
Annals of Oncology 2005 16(5):749-755
M.L. Harrison, P. Hoskins, A. du Bois, M. Quinn, G.J.S. Rustin, J.A.
Ledermann, S. Baron-Hay and M.L. Friedlander. Gynecologic Oncology. Small
cell of the ovary, hypercalcemic typeAnalysis of combined experience and
recommendation for management. A GCIG study. Volume 100, Issue 2, Pages
225-448 (February 2006).
Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft
Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial
Philipp Harter, Andreas du Bois, Maik Hahmann, Annette Hasenburg,
Alexander Burges, Sibylle Loibl, Martina Gropp, Jens Huober, Daniel Fink,
Willibald Schröder, Karsten Muenstedt, Barbara Schmalfeldt, Guenter Emons,
Jacobus Pfisterer, Kerstin Wollschlaeger, Hans-Gerd Meerpohl, Georg-Peter
Breitbach, Berno Tanner and Jalid Sehouli
Hoskins P, Eisenhauer E, Fisher B, Vergote I, Dubuc J, Stuart G, Grimshaw R, Plante M, Vermorken J, Oza A. Sequential couplets of cisplatin/topotecan and cisplatin/paclitaxel as first-line therapy for advanced epithelial ovarian cancer: An NCIC Clinical Trials Group phase II study. Proc Am Soc Clin Oncol 18:357a, 1999.
Ref Type: Abstract
Keywords: IND.106/GYN
Notes: Abstract #1378
Hoskins P, Eisenhauer E, Vergote I, Dubuc-Lissoir J, Fisher B, Grimshaw R, Oza A, Plante M, Stuart G, Vermorken J. Phase II feasibility study of sequential couplets of cisplatin/topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer. J Clin Oncol 18(24):4038-44, 2000.
Keywords: IND.106/GYN
Kristensen G, Vergote I, Stuart G, Izquierdo Delso M, Mirza MR, Aavall-Lundquist E, Lopez AB, Ridderheim M, Havesten H, Scheistroen M, Eisenhauer E. First line treatment of ovarian cancer FIGO stage IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin. Interim results of an NSGO-EORTC-NCIC CTG Gynaecological Cancer Intergroup phase III trial. Proc Am Soc Clin Oncol 21(part 1):202a, 2002.
Ref Type: Abstract
Keywords: EORTC/GYN/intergroup/NCIC CTG/NSGO/OV.14/GCIG
Notes: Abstract #805
Results of the 2006 Innsbruck International Consensus Conference on
intraperitoneal chemotherapy in patients with ovarian cancer
Christian Marth, Joan L. Walker, Richard R. Barakat, Antonio Casado, Angiolo
Gadducci, Brigitte Miller, Franco Odicino, Eric Pujade-Lauraine, Jalid
Sehouli, Claes Tropé, Lari Wenzel, Alain G. Zeimet
Cancer. 2007 Feb 15;109(4):645-9.
Is It Time for Some New Approaches for Treating Advanced Ovarian Cancer?
William P. McGuire J Natl Cancer Inst 2006 98: 1024-1026.
Randomized Phase III Trial of Topotecan Following Carboplatin and
Paclitaxel in First-line Treatment of Advanced Ovarian Cancer: A
Gynecologic Cancer Intergroup Trial of the AGO-OVAR and GINECO
Jacobus Pfisterer, Beatrice Weber, Alexander Reuss, Rainer Kimmig, Andreas
du Bois, Uwe Wagner, Hugues Bourgeois, Werner Meier, Serban Costa, Jens-Uwe
Blohmer, Alain Lortholary, Sigrid Olbricht, Anne Stahle, Christian
Jackisch, Anne-Claire Hardy-Bessard, Volker Mobus, Jens Quaas, Barbara
Richter, Willibald Schroder, Jean-Francois Geay, Hans-Joachim Luck, Walther
Kuhn, Harald Meden, Ulrike Nitz, and Eric Pujade-Lauraine
J Natl Cancer Inst 2006 98: 1036-1045.
Pretreatment CA-125 and Risk of Relapse in Advanced Ovarian Cancer
Markman, Maurie , P.Y. Liu, Mace L. Rothenberg, Bradley J. Monk, Mark
Brady, and David S. Alberts J Clin Oncol 2006;24 1454-1458
http://www.jco.org/cgi/content/abstract/24/9/1454?etoc or PDF Version
Parmar MKB, Ledermann JA, Colombo N, du Bois A, Delaloye J-F, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Tropé C; ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361: 2099-2106 (2003)
Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With
Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the
AGO-OVAR, the NCIC CTG, and the EORTC GCG
Jacobus Pfisterer, Marie Plante, Ignace Vergote, Andreas du Bois, Hal
Hirte, Angel J. Lacave, Uwe Wagner, Anne Stahle, Gavin Stuart, Rainer
Kimmig, Sigrid Olbricht, Tien Le, Janusz Emerich, Walther Kuhn, James
Bentley, Christian Jackisch, Hans-Joachim Luck, Justine Rochon, Annamaria
Hayden Zimmermann, and Elizabeth Eisenhauer
J Clin Oncol published 11 September 2006, 10.1200/JCO.2006.06.0913
PDF
Piccart M, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson R, Swenerton K, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen J, Zee B, Paul J, Baron B, Pecorelli S. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. J Natl Cancer Inst 92(9):699-708, 2000.
Keywords: intergroup/OV.10/GYN/EORTC
Piccart M, Bertelsen K, Stuart G, Cassidy J, Vergote I, Simonsen E, Swenerton K, Kaye S, Roy J, Baron B. Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer. Ann Oncol 13(Suppl.5):109, 2002.
Ref Type: Abstract
Keywords: EORTC-GCG/GYN/intergroup/NCIC CTG/NOCOVA/OV.10/Scottish Group Investigators
Notes: Abstract #395O
Piccart M, Stuart G, Cassidy J, Bertelsen K, Parmar M, Eisenhauer E, Kaye S, Trope C, Swenerton K, Harper P, Vermorken J. Intergroup collaboration in ovarian cancer: A giant step forward. Ann Oncol 10(Suppl 1):83-6, 1999.
Keywords: intergroup/GYN/general/review/IND.
Rothenberg M, Liu PY, Braly PS, Wilcznski S, Hannigan EV, Wadler S, Stuart G, Jiang C, Markman M, Alberts DS. Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian
cancer: results from an intergroup phase II trial. J Clin Oncol 21 (7): 1313-9, 2003.
Rothenberg M, Liu PY, Wilcznski S, Braly PS, Wadler S, Stuart G, Hannigan EV, Bonebrake AJ, Alberts DS, Markman M. Excellent 2 year survival in women with optimally debulked ovarian cancer treated with intraperitoneal and intravenous chemotherapy: a SWOG-ECOG-NCIC CTG study (S9619).
Proc.Am.Soc.Clin.Oncol. 21 (part 1), 203a.2002.
Rustin, GJS. Using CA-125 to Measure Response. J Clin Oncol 22 (20), 2004.
Rustin
Comparison of CA-125 and Standard Definitions of Progression of Ovarian
Cancer in the Intergroup Trial of Cisplatin and Paclitaxel Versus Cisplatin
and Cyclophosphamide
Gordon J.S. Rustin, Petra Timmers, Ann Nelstrop, Gavin Shreeves, Soeren M.
Bentzen, Benoit Baron, Martine J. Piccart, Kamma Bertelsen, Gavin Stuart,
James Cassidy, and Elizabeth Eisenhauer
J Clin Oncol 2006;24 45-51 http://www.jco.org/cgi/content/abstract/24/1/45?etoc
PDF
Stuart G, Bertelsen K, Mangioni C, Trope C, James K, Cassidy J, Kaye S, Timmers P, Roy JA, Piccart M. Updated analysis shows a highly significant improved overall survival for cisplatin-paclitaxel as first line treatment of advanced ovarian cancer: Mature results of the EORTC-GCCG, NOCOVA, NCIC CTG and Scottish Intergroup trial. Proc Am Soc Clin Oncol 17:361, 1998.
Ref Type: Abstract
Keywords: intergroup/OV.10/GYN/EORTC
Notes: Abstract #1394
Stuart G. First line treatment of ovarian cancer FIGO stage IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin. Interim results of an NSGO-EORTC-GCG--NCIC CTG Gynaecological Cancer Intergroup phase III trial (submitted). Eur Soc Gyn Oncol, 2003.
Ref Type: Abstract
Keywords: EORTC/GCG/GYN/intergroup/NCIC CTG/NSGO/OV.14
CpG Island Methylation of DNA Damage Response Genes in Advanced Ovarian Cancer
Jens M. Teodoridis, Jacqueline Hall, Sharon Marsh, Hilary D. Kannall,
Catriona Smyth, Jorge Curto, Nadeem Siddiqui, Hani Gabra, Howard L. McLeod,
Gordon Strathdee, and Robert Brown
Cancer Res 2005;65 8961-8967
Thigpen JT, Brady M, Homesley H, Malfetano J, DuBeshter B, Burger R, Liao S. Phase III Trial of Doxorubicin With or Without Cisplatin in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study
J Clin Oncol 22(19):3902-3908, 2004
Phase III Randomized Trial of Docetaxel-Carboplatin Versus
Paclitaxel-Carboplatin as First-line Chemotherapy for Ovarian Carcinoma
Paul A. Vasey, Gordon C. Jayson, Alan Gordon, Hani Gabra, Rob Coleman,
Ronnie Atkinson, David Parkin, James Paul, Andrea Hay, Stan B. Kaye. On
behalf of the Scottish Gynaecological Cancer Trials Group.
J Natl Cancer Inst 2004 96: 1682-1691.
Vergote I, Kristensen G, Stuart G, Aavall-Lundquist E, Kaern J, Eisenhauer E. First line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin (TEC) vs. paclitaxel/carboplatin (TC). Interim results of an NSGO-EORTC-GCG-NCIC CTG Gynaecological Cancer Intergroup phase III trial. Presented: Int Gyn Cancer Soc, 2002.
Ref Type: Abstract
Keywords: EORTC/GCIG/GYN/intergroup/NCIC CTG/NSGO/OV.14
Vergote I, Rustin G, Eisenhauer E, Kristensen G, Pujade-Lauraine E, Parmar M, Friedlander M, Jakobsen A, Vermorken J. New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 92(18):1534, 2000.
Keywords: GCIG/general/review/GYN/intergroup
Vermorken J. Intergroup collaboration in ovarian cancer: The Gynecologic Cancer Intergroup (GCIG). Int J Gynecol Cancer 11(Suppl. 1):73-6, 2001.
Keywords: GCIG/general/review/GYN/intergroup
Walker H, Stuart G, Bacon M, Eisenhauer E, Bacon E, Tu D, Zee B. Comparative cost-effectiveness of paclitaxel-cisplatin vs. cyclophosphamide-cisplatin in women with advanced epithelial ovarian cancer: Results from a randomized trial. Proc Am Soc Clin Oncol 19:379a, 2000.
Ref Type: Abstract
Keywords: OV.10/GYN/intergroup/EORTC
Notes: Abstract #1501
Other References
Impact and Perceptions of Mandatory Tumor Biopsies for Correlative Studies
in Clinical Trials of Novel Anticancer Agents
Mark Agulnik, Amit M. Oza, Gregory R. Pond, and Lillian L. Siu
JCO Oct 20 2006: 48014807.
Intraperitoneal Therapy for Ovarian Cancer: A Treatment Ready for Prime
Time Deborah K. Armstrong and Mark F. Brady
JCO Oct 1 2006: 45314533.
Ben Davidson, Virginia Espina, Seth M. Steinberg, Vivi Ann Florenes, Lance
A. Liotta, Gunnar B. Kristensen, Claes G. Trope, Aasmund Berner, and Elise
C. Kohn. Proteomic Analysis of Malignant Ovarian Cancer Effusions as a
Tool for Biologic and Prognostic Profiling. Clin Cancer Res 2006;12 791-799.
Craig C. Earle, Deborah Schrag, Bridget A. Neville, K. Robin Yabroff, Marie
Topor, Angela Fahey, Edward L. Trimble, Diane C. Bodurka, Robert E.
Bristow, Michael Carney, and Joan L. Warren. Effect of Surgeon Specialty
on Processes of Care and Outcomes for Ovarian Cancer
Patients. J Natl
Cancer Inst 2006; 98: 172-180.
Friedlander, M. Guidelines for the treatment of recurrent and metastatic cervical cancer. The Oncologist 7:342-7, 2002.
Fujiwara K, Kigawa J, Hasegawa K, Nishimura T., Umezaki N, Ando M, Itamochi
H, Yamaguchi S, Oda T, Terakawa N, Kohshima I, Kohno I. Effect of simple
omentoplasty and omentopexy in the prevention of complications after pelvic
lymphadenectomy. Int J Gynecol Cancer 13:31-66, 2003.
Fujiwara K, Sakuragi N, Suzuki S, Yoshida N, Maehata K, Nishiya M, Koshida
T, Sawai H, Aotani E, Kohno I. First-line intraperitoneal
carboplatin-based chemotherapy for 165 patients with epithelial ovarian
carcinoma: results of long-term follow-up. Gynecol Oncol. 90:637-643, 2003.
Fujiwara K, Suzuki S, Ishikawa H, Oda T, Aotani E, Kohno I. Preliminary
toxicity analysis of intraperitoneal carboplatin in combination with
intravenous paclitaxel chemotherapy for patients with carcinoma of the
ovary, peritoneum, or fallopian tube. Int J Gynecol Cancer 15:426431, 2005.
Elfriede R. Greimel, Vesna Bjelic-Radisic, Jacobus Pfisterer, Felix
Hilpert, Fedor Daghofer, and Andreas du Bois. Randomized Study of the Arbeitsgemeinschaft Gynaekologische Onkologie
Ovarian Cancer Study Group Comparing Quality of Life in Patients With
Ovarian Cancer Treated With Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel.
JCO Feb 1 2006: 579586.
Gronlund, B. CA-125 Response Criteria vs. RECIST for Prognostication During Second-Line Chemo of Ovarian Carcinoma. J Clin Oncol 22 (20), 2004.
Gronlund
Kanamori Y, Kigawa J, Itamochi H, Sultana H, Suzuki M, Ohwada M, Kamura T,
Sugiyama T, Kikuchi Y, Kita T, Fujiwara K, Terakawa N. PTEN expression is
associated with prognosis for patients with advanced endometrial carcinoma
undergoing postoperative chemotherapy. Int J Cancer 100:686-689, 2002
Relationships of Human Papillomavirus Type, Qualitative Viral Load, and
Age with Cytologic Abnormality
Melinda Butsch Kovacic, Philip E. Castle, Rolando Herrero, Mark
Schiffman,
Mark E. Sherman, Sholom Wacholder, Ana C. Rodriguez, Martha L. Hutchinson,
M. Concepción Bratti, Allan Hildesheim, Jorge Morales, Mario Alfaro, and
Robert D. Burk
Cancer Res 2006 66: 10112-10119.
Charles N. Landen, Jr., Chunhua Lu, Liz Y. Han, Karen T. Coffman,
Elizabeth Bruckheimer, Jyotsnabaran Halder, Lingegowda S. Mangala,
William M. Merritt, Yvonne G. Lin, Changhou Gao, Rosemarie Schmandt,
Aparna A. Kamat, Yang Li, Premal Thaker, David M. Gershenson, Nila U.
Parikh, Gary E. Gallick, Michael S. Kinch, and Anil K. Sood
Efficacy and Antivascular Effects of EphA2 Reduction With an Agonistic
Antibody in Ovarian Cancer
J Natl Cancer Inst 2006; 98: 1558-1570.
Maurie Markman and Joan L. Walker. Intraperitoneal Chemotherapy of Ovarian
Cancer: A Review, With a Focus on Practical Aspects of Treatment. J Clin
Oncol published 6 February 2006, 10.1200/JCO.2005.05.2456.
Malignant Ovarian Germ Cell Tumors: Identification of Novel Prognostic
Markers and Long-Term Outcome After Multimodality Treatment
Nirupa Murugaesu, Peter Schmid, Gairin Dancey, Roshan Agarwal, Lydia
Holden, Iain McNeish, Philip M. Savage, Edward S. Newlands, Gordon J.S.
Rustin, and Michael J. Seckl
JCO Oct 20 2006: 48624866.
Oishi T, Kigawa J, Fujiwara K, Fujiwara M, Numa F, Aotani E, Katsumata N,
Kohno I, Kato H, Terakawaa N. A feasibility study on biweekly
administration of docetaxel for patients with recurrent ovarian cancer.
Gynecol Oncol 90:421-424, 2003.
Sandro Pignata, Sabino De Placido, Rosalbino Biamonte, Giovanni Scambia,
Giovanni Di Vagno, Giuseppe Colucci, Antonio Febbraro, Marco Marinaccio,
Alessandra Vernaglia Lombardi, Luigi Manzione, Giacomo Cartenì, Mario
Nardi, Saverio Danese,
Maria Rosaria Valerio, Andrea de Matteis, Bruno Massidda, Giampietro
Gasparini, Massimo Di Maio, Carmela Pisano and Francesco Perrone. Residual
neurotoxicity in ovarian cancer patients in clinical remission after
first-line chemotherapy with carboplatin and paclitaxel: The Multicenter
Italian Trial in Ovarian cancer (MITO-4) retrospective study. BMC Cancer,
6:5, 2006.
Pignata, Sandro, Giovanni Scambia, Antonella Savarese, Enrico Breda, Paolo
Scollo, Rocco De Vivo, Emanuela Rossi, Vittorio Gebbia, Donato Natale,
Filomena Del Gaizo, Emanuele Naglieri, Antonella Ferro, Pietro Musso,
Alfonso Maria D'Arco, Roberto Sorio, Carmela Pisano, Massimo Di Maio,
Giuseppe Signoriello, Annalisa Annunziata, and Francesco Perrone for the
MITO Investigators. Safety of a 3-weekly schedule of carboplatin plus
pegylated liposomal doxorubicin as first line chemotherapy in patients with
ovarian cancer: preliminary results of the MITO-2 randomized trial. BMC
Cancer 2006, 6:202.
Deborah Schrag, Craig Earle, Feng Xu, Katherine S. Panageas, K. Robin
Yabroff, Robert E. Bristow, Edward L. Trimble, and Joan L.
Warren. Associations Between Hospital and Surgeon Procedure Volumes and
Patient Outcomes After Ovarian Cancer
Resection. J Natl
Cancer Inst 2006; 98: 163-171.
Trimble E, Schoenfeldt M. Current clinical trials in cervical cancer. Oncology, 17(1):(in press), 2003.
Trimble E, Schoenfeldt M. Current clinical trials in endometrial cancer. Oncology, 17(2):(in review), 2003.
Trimble E, Schoenfeldt M, Cornelison TL, Wright JJ, Kolker A, Christian M. Current clinical trials in ovarian cancer. Part I. Oncology, 16(11):1498-1507, 2002.
Trimble E, Schoenfeldt M, Cornelison TL, Wright JJ, Kolker A, Christian M. Current clinical trials in ovarian cancer. Part II. Oncology, 16(12):1660-1667, 2002.
|
